This has just come out and is worth looking at. A clinical trial called HERMES was presented at ASCO this week - one of the biggest cancer conferences in the world. It compared two radiotherapy sessions against the standard five for localised prostate cancer. The outcomes were the same. Same cancer control. Similar side effects. Now - this will not apply to every man. Stage and tumour type matter. Your oncologist has the full picture. But you cannot ask the question if you do not know the option exists. 'Is the two-session course right for my case?' That is a conversation worth having before any treatment starts. Has anyone here been through prostate radiotherapy? Did you know at the time what your options were - or did you find out later? I would like to hear your experience.

I want to share something that comes up a lot in conversations with men who have been through prostate cancer treatment. They describe feeling heavy. Slow. Less like themselves. Their partners describe watching them change and not knowing what to name it. Most put it down to putting up the good fight and they are just tired. This is more true than they know. A new study in Nature has mapped exactly what happens to muscle at the cellular level during androgen deprivation therapy. The mitochondria - the energy engines inside muscle cells - are being depleted. That is the mechanism. It is documented. This is not weakness or depression. It is biology. And here is the part that matters most: men who start resistance exercise before treatment - and keep it going - slow the loss significantly. That is something to raise with your doctor before the first treatment, not six months in. Has anyone in the community been through this? I would like to know what helped.

This is documented in Oncology Nursing News.... Darolutamide Shows Less Cognitive Decline Than Enzalutamide in Advanced Prostate Cancer. When a man goes on hormone therapy for prostate cancer - the focus is almost always on the cancer. Is it working? Are the numbers moving? Good. What next? Nobody talks about the brain. New research has looked at two of the most commonly used hormone therapy drugs and compared how they affect cognition. The difference is significant. One causes measurably more cognitive decline than the other. For the men here who are on treatment, or whose partners are watching for changes - this is not something you imagined. It is biology. And it is something to raise with your doctor. Has anyone in the community experienced this? Or noticed it in someone they care about? I would genuinely like to know what people have seen.

I want to address something that comes up regularly in conversations about BPH, because I think a lot of men - and maybe some in this community - are still working from outdated information. The single most common reason men avoid dealing with BPH beyond medication is that they heard "surgery" at some point and stopped being curious. Older surgical approaches were significant. Recovery was real. The fear was understandable. But the direction of the BPH field for the past several years has been entirely away from that. Minimally invasive, office-based, same-day procedures that do not require general anaesthesia, have short recovery times, and are specifically designed to preserve sexual function. A Urology Times overview published this week confirmed where the space is going: three of these minimally invasive approaches have now reached Category I status, and two new devices received FDA approval in the past few weeks. I cannot recommend any particular approach. That is not what we do here. But, I can make you aware that new options are available - a simple search will bring up the results. If you or someone you know has been managing BPH with medication that is no longer fully working - or if you know someone who shut down the conversation years ago - this is worth revisiting. What is stopping the men in your life from having this conversation with a urologist? I am genuinely curious about what the real barriers are for people here.

This is one I find genuinely exciting and I wanted to share it here. We have all been there for treatment of one thing or another, not necessarily cancer, but other things where the doctor tries one medicine to see how we react to it. It is not their fault, everyone is different and we all react differently to things. Trial and error is all there was before now. A systematic review published in April 2026 and then mentioned in Science Direct and UroToday May 2026, looked at patient-derived organoids - lab-grown, three-dimensional models made from a man's own prostate cancer cells. The review confirmed these models are advancing toward clinical use for treatment selection. The practical implication is significant: these mini-tumours are close enough to the real thing that researchers can test which drugs work on them before any drug is given to the patient. The idea of personalised treatment - matching the therapy to the specific biology of that man's cancer rather than working through a standard sequence - moves much closer to reality. We are not at a point where this is standard clinical practice. I want to be clear about that. But I share it because I think this community deserves to know where the science is headed. The years of uncertainty - will this treatment work? why did the last one not? - may eventually be addressable before treatment begins rather than after. Has anyone in this community had genomic or molecular testing done to guide their treatment choices? I am curious how many people are already having this conversation with their doctors.